FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891131925> ?p ?o ?g. }

• W2891131925 abstract "10527 Background: The optimal type and intensity of CHT in the treatment of STET is still a matter of debate. The CWS group has treated STET similar to rhabdomyosarcoma. We have analyzed the prognosis of STET in relation to the CHT regimens used in three consecutive CWS studies CWS-91, -96 and CWS- 2002P. Methods: 243 pts with localized STET were included. Their median age was 12 (range 0.1-29) yrs. In the CWS-91 pts with primary tumor resection (IRSG I and II) were treated with VACA (vincristine (VCR), actinomycin D (Act D), cyclophosphamide (CYC), doxorubicin (DOX), for 10 or 20 weeks. All other CWS-91 pts (high risk group, HRG) received EVAIA (ifosfamide (IFO) instead of CYC plus VP16) for 37 weeks. In the CWS-96 and CWS-2002P all STET pts were allocated to the HRG. In CWS-96 therapy was randomized: VAIA (IFO, DOX, Act D, VCR) vs. CEVAIE (Epi-DOX instead of DOX, plus carboplatin and VP16), for 25 weeks. In CWS-2002P VAIA (25 weeks) plus maintenance CHT with CYC and vinblastine (VBL) for 26 weeks were used. The cumulative doses varied: IFO 24-72 g/m², CYC 4.8-7.35 g/m², DOX 120-360 mg/m², Act D 3-9 mg/m², VP16 1.8-5.4 g/m². Irradiation was stratified depending on results of the primary or secondary resection and response. Results: 5 yr event free (EFS) and overall survival (OS) were 64% and 73%. The median observation time of survivors was 9 yrs. 5yr EFS and OS by study were: CWS-91 64 % and 72 %, CWS-96 57% and 70 %, CWS-2002P 78 % and 86 % respectively (n.s.). 5 yr EFS and OS for VACA arm were 79% and 90%. 5 yr EFS and OS by CHT for HRG were: EVAIA 57% and 65%, VAIA 64% and 80%, CEVAIE 45% and 54%, VAIA with CYC/VBL 84% and 87%, respectively (p = 0 .003). 5yr EFS and OS for irradiated (n = 181) vs. not irradiated (n = 48) patients were 63 % and 72% vs. 63% and 79%, respectively. Conclusions: The outcomes between CHT arms differed significantly: CEVAIA correlated with the worst outcome while VAIA with CYC/VBL showed the best results. A small group of low risk patients have an excellent prognosis with substantially reduced CHT. Ewing tumors are biologically heterogeneous and more diversification in therapy stratification is warranted to avoid overtreatment." @default.
• W2891131925 created "2018-09-27" @default.
• W2891131925 creator A5002688480 @default.
• W2891131925 creator A5005661631 @default.
• W2891131925 creator A5008197312 @default.
• W2891131925 creator A5011059803 @default.
• W2891131925 creator A5020975466 @default.
• W2891131925 creator A5027746254 @default.
• W2891131925 creator A5042718514 @default.
• W2891131925 creator A5042744031 @default.
• W2891131925 creator A5048230786 @default.
• W2891131925 creator A5051748483 @default.
• W2891131925 creator A5063765068 @default.
• W2891131925 creator A5065181259 @default.
• W2891131925 creator A5077706742 @default.
• W2891131925 creator A5082438382 @default.
• W2891131925 date "2017-05-20" @default.
• W2891131925 modified "2023-10-02" @default.
• W2891131925 title "Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS)." @default.
• W2891131925 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10527" @default.
• W2891131925 hasPublicationYear "2017" @default.
• W2891131925 type Work @default.
• W2891131925 sameAs 2891131925 @default.
• W2891131925 citedByCount "0" @default.
• W2891131925 crossrefType "journal-article" @default.
• W2891131925 hasAuthorship W2891131925A5002688480 @default.
• W2891131925 hasAuthorship W2891131925A5005661631 @default.
• W2891131925 hasAuthorship W2891131925A5008197312 @default.
• W2891131925 hasAuthorship W2891131925A5011059803 @default.
• W2891131925 hasAuthorship W2891131925A5020975466 @default.
• W2891131925 hasAuthorship W2891131925A5027746254 @default.
• W2891131925 hasAuthorship W2891131925A5042718514 @default.
• W2891131925 hasAuthorship W2891131925A5042744031 @default.
• W2891131925 hasAuthorship W2891131925A5048230786 @default.
• W2891131925 hasAuthorship W2891131925A5051748483 @default.
• W2891131925 hasAuthorship W2891131925A5063765068 @default.
• W2891131925 hasAuthorship W2891131925A5065181259 @default.
• W2891131925 hasAuthorship W2891131925A5077706742 @default.
• W2891131925 hasAuthorship W2891131925A5082438382 @default.
• W2891131925 hasConcept C121332964 @default.
• W2891131925 hasConcept C126322002 @default.
• W2891131925 hasConcept C142724271 @default.
• W2891131925 hasConcept C143998085 @default.
• W2891131925 hasConcept C2776694085 @default.
• W2891131925 hasConcept C2778256501 @default.
• W2891131925 hasConcept C2780844630 @default.
• W2891131925 hasConcept C62520636 @default.
• W2891131925 hasConcept C71924100 @default.
• W2891131925 hasConcept C93038891 @default.
• W2891131925 hasConceptScore W2891131925C121332964 @default.
• W2891131925 hasConceptScore W2891131925C126322002 @default.
• W2891131925 hasConceptScore W2891131925C142724271 @default.
• W2891131925 hasConceptScore W2891131925C143998085 @default.
• W2891131925 hasConceptScore W2891131925C2776694085 @default.
• W2891131925 hasConceptScore W2891131925C2778256501 @default.
• W2891131925 hasConceptScore W2891131925C2780844630 @default.
• W2891131925 hasConceptScore W2891131925C62520636 @default.
• W2891131925 hasConceptScore W2891131925C71924100 @default.
• W2891131925 hasConceptScore W2891131925C93038891 @default.
• W2891131925 hasLocation W28911319251 @default.
• W2891131925 hasOpenAccess W2891131925 @default.
• W2891131925 hasPrimaryLocation W28911319251 @default.
• W2891131925 hasRelatedWork W2560302832 @default.
• W2891131925 isParatext "false" @default.
• W2891131925 isRetracted "false" @default.
• W2891131925 magId "2891131925" @default.
• W2891131925 workType "article" @default.